New Zealand markets closed

Poseida Therapeutics, Inc. (PSTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
2.6400-0.0300 (-1.12%)
At close: 04:00PM EST
2.6600 +0.02 (+0.76%)
After hours: 04:16PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) 251.49M
Enterprise value 98.92M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)4.64
Price/book (mrq)2.03
Enterprise value/revenue 1.99
Enterprise value/EBITDA -0.84

Trading information

Stock price history

Beta (5Y monthly) -0.01
52-week change 3-48.24%
S&P500 52-week change 314.90%
52-week high 38.8200
52-week low 31.5400
50-day moving average 32.3167
200-day moving average 32.7004

Share statistics

Avg vol (3-month) 3489.8k
Avg vol (10-day) 3523.2k
Shares outstanding 595.62M
Implied shares outstanding 695.62M
Float 853.84M
% held by insiders 128.26%
% held by institutions 152.32%
Shares short (14 Nov 2023) 43.59M
Short ratio (14 Nov 2023) 47.41
Short % of float (14 Nov 2023) 45.79%
Short % of shares outstanding (14 Nov 2023) 43.77%
Shares short (prior month 12 Oct 2023) 43.89M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2022
Most-recent quarter (mrq)29 Sept 2023


Profit margin -264.07%
Operating margin (ttm)-387.32%

Management effectiveness

Return on assets (ttm)-25.05%
Return on equity (ttm)-77.30%

Income statement

Revenue (ttm)49.76M
Revenue per share (ttm)0.57
Quarterly revenue growth (yoy)-92.00%
Gross profit (ttm)-22.41M
EBITDA -131.28M
Net income avi to common (ttm)-131.4M
Diluted EPS (ttm)-1.5400
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)238.84M
Total cash per share (mrq)2.5
Total debt (mrq)86.26M
Total debt/equity (mrq)69.76%
Current ratio (mrq)3.28
Book value per share (mrq)1.29

Cash flow statement

Operating cash flow (ttm)-61.02M
Levered free cash flow (ttm)-3.68M